Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations

Journal of Clinical Oncology

Volumn 34, Issue 8, 2016, Pages 794-802

  Liu, Xuewen ^c   Jia, Yuxia ^d   Stoopler, Mark B ^a   Shen, Yufeng ^a   Cheng, Haiying ^b   Chen, Jinli ^a   Mansukhani, Mahesh ^a   Koul, Sanjay ^a   Halmos, Balazs ^a   Borczuk, Alain C ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; DNA; ISOENZYME; MET PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SCATTER FACTOR RECEPTOR;

ADENOCARCINOMA CELL LINE; ADULT; AGED; ARTICLE; CDH4 GENE; CDH7 GENE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; EXOME; EXON; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; KRAS GENE; LAMB4 GENE; LMTK2 GENE; LUNG ALVEOLUS CELL; LUNG CARCINOMA; MALE; MET GENE; MOLECULAR PATHOLOGY; NEXT GENERATION SEQUENCING; NOTCH GENE; PIK3CA GENE; PRIORITY JOURNAL; PULMONARY SARCOMATOID CARCINOMA; RASA1 GENE; RB1 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMATOID CARCINOMA; SCAF1 GENE; STK11 GENE; STOMACH ADENOCARCINOMA; TP53 GENE; TREATMENT RESPONSE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CASE REPORT; CELL GROWTH; COHORT ANALYSIS; DNA MUTATIONAL ANALYSIS; GENE SILENCING; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MISSENSE MUTATION; PATHOLOGY; PHYSIOLOGY; POINT MUTATION; PROCEDURES; SARCOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL GROWTH PROCESSES; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHATIDYLINOSITOL 3-KINASES; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; SARCOMA;

EID: 84962609567     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.0674     Document Type: Article

References (41)

1. Pathology and Genetics of Tumours the Lung, Pleura, Thymus and Heart. Lyon, France, IARC Press, 2004, p 341
2. Yendamuri S, Caty L, Pine M, et al: Outcomes of sarcomatoid carcinoma of the lung: A Surveillance, Epidemiology, and End Results database analysis. Surgery 152:397-402, 2012
3. Martin LW, Correa AM, Ordonez NG, et al: Sarcomatoid carcinoma of the lung: A predictor of poor prognosis. Ann Thorac Surg 84:973-980, 2007
4. Mochizuki T, Ishii G, Nagai K, et al: Pleomorphic carcinoma of the lung: Clinicopathologic characteristics of 70 cases. Am J Surg Pathol 32:1727-1735, 2008
5. Vieira T, Girard N, Ung M, et al: Efficacy of firstline chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol 8:1574-1577, 2013
6. Bae HM, Min HS, Lee SH, et al: Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer 58:112-115, 2007
7. Italiano A, Cortot AB, Ilie M, et al: EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 125:2479-2482, 2009
8. Leone A, Graziano P, Gasbarra R, et al: Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer 128:732-735, 2011; author reply 736
9. Pelosi G, Gasparini P, Cavazza A, et al: Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer 77:507-514, 2012
10. Vieira T, Antoine M, Ruppert AM, et al: Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. Lung Cancer 85:276-281, 2014
11. Kaira K, Horie Y, Ayabe E, et al: Pulmonary pleomorphic carcinoma: A clinicopathological study including EGFR mutation analysis. J Thorac Oncol 5:460-465, 2010
12. Chang YL, Wu CT, Shih JY, et al: EGFR and p53 status of pulmonary pleomorphic carcinoma: Implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. Ann Surg Oncol 18:2952-2960, 2011
13. Lee S, Kim Y, Sun JM, et al: Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol 137:1203-1211, 2011
14. Ushiki A, Koizumi T, Kobayashi N, et al: Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: Response to gefitinib and clinical outcome. Jpn J Clin Oncol 39:267-270, 2009
15. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706-714, 2007
16. Douville C, Carter H, Kim R, et al: CRAVAT: Cancer-related analysis of variants toolkit. Bioinformatics 29:647-648, 2013
17. Wong WC, Kim D, Carter H, et al: CHASM and SNVBox: Toolkit for detecting biologically important single nucleotide mutations in cancer. Bioinformatics 27:2147-2148, 2011
18. Choi Y, Sims GE, Murphy S, et al: Predicting the functional effect of amino acid substitutions and indels. PLoS One 7:e46688, 2012
19. Zhang Z, Lee JC, Lin L, et al: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44:852-860, 2012
20. Peng H, Wen J, Li H, et al: Drug inhibition profile prediction for NFkappaB pathway in multiple myeloma. PLoS One 6:e14750, 2011
21. Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543-550, 2014
22. Ma PC, Kijima T, Maulik G, et al: C-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272-6281, 2003
23. Asaoka Y, Tada M, Ikenoue T, et al: Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem Biophys Res Commun 394:1042-1046, 2010
24. Kong-Beltran M, Seshagiri S, Zha J, et al: Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66:283-289, 2006
25. Spoerke JM, O'Brien C, Huw L, et al: Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 18:6771-6783, 2012
26. Chaft JE, Arcila ME, Paik PK, et al: Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 11:485-491, 2012
27. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26, 2011
28. Kris MG, Johnson BE, Berry LD, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998-2006, 2014
29. Ichihara S, Toyooka S, Fujiwara Y, et al: The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120:1239-1247, 2007
30. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17, 2005
31. Linardou H, Dahabreh IJ, Kanaloupiti D, et al: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFRtargeted agents: A systematic review and metaanalysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962-972, 2008
32. Lefebvre J, Ancot F, Leroy C, et al: Met degradation: More than one stone to shoot a receptor down. FASEB J 26:1387-1399, 2012
33. Dhanasekaran SM, Balbin OA, Chen G, et al: Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and hippo pathway genes. Nat Commun 5:5893, 2014
34. Seo JS, Ju YS, Lee WC, et al: The transcriptional landscape andmutational profile of lung adenocarcinoma. Genome Res 22:2109-2119, 2012
35. Okuda K, Sasaki H, Yukiue H, et al: Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 99:2280-2285, 2008
36. Onozato R, Kosaka T, Kuwano H, et al: Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 4:5-11, 2009
37. Weidner KM, Arakaki N, Hartmann G, et al: Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A 88:7001-7005, 1991
38. Stoker M, Gherardi E, Perryman M, et al: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327:239-242, 1987
39. Jenkins RW, Oxnard GR, Elkin S, et al: Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. Clin Lung Cancer [epub ahead of print on February 7, 2015]
40. Wang L, Hu H, Pan Y, et al: PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One 9:e88291, 2014
41. Camidge DR, Ou S-HI, Shapiro G, et al: Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 32:506s, 2014(suppl 15s; abstr 8001)